Claire Booth, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Severe Combined Immunodeficiency | 6 | 2024 | 227 | 0.990 |
Why?
|
Agammaglobulinemia | 5 | 2024 | 171 | 0.800 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 4 | 2024 | 269 | 0.710 |
Why?
|
Immunologic Deficiency Syndromes | 4 | 2023 | 547 | 0.610 |
Why?
|
Hematopoietic Stem Cell Transplantation | 15 | 2024 | 5671 | 0.600 |
Why?
|
Adenosine Deaminase | 5 | 2023 | 251 | 0.490 |
Why?
|
Lymphoproliferative Disorders | 2 | 2022 | 531 | 0.430 |
Why?
|
Granulomatous Disease, Chronic | 2 | 2020 | 173 | 0.300 |
Why?
|
Lentivirus | 2 | 2021 | 508 | 0.290 |
Why?
|
Antigens, CD34 | 2 | 2020 | 658 | 0.270 |
Why?
|
Piebaldism | 1 | 2024 | 4 | 0.250 |
Why?
|
Receptors, Cell Surface | 1 | 2010 | 2822 | 0.190 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2872 | 0.180 |
Why?
|
Sexual Development | 1 | 2020 | 40 | 0.170 |
Why?
|
Transplantation Conditioning | 4 | 2020 | 1590 | 0.170 |
Why?
|
Urogenital System | 1 | 2020 | 88 | 0.170 |
Why?
|
Antigens, CD | 1 | 2010 | 4003 | 0.170 |
Why?
|
Chromosomes, Human, X | 1 | 2020 | 321 | 0.150 |
Why?
|
Urogenital Abnormalities | 1 | 2020 | 261 | 0.140 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2017 | 37 | 0.140 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 3029 | 0.130 |
Why?
|
Mutation | 5 | 2024 | 30052 | 0.130 |
Why?
|
Child, Preschool | 13 | 2024 | 42230 | 0.120 |
Why?
|
Genetic Vectors | 2 | 2021 | 3395 | 0.120 |
Why?
|
Infant | 11 | 2024 | 36192 | 0.120 |
Why?
|
Child | 15 | 2024 | 80153 | 0.100 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2017 | 612 | 0.100 |
Why?
|
Homeodomain Proteins | 1 | 2019 | 2416 | 0.080 |
Why?
|
Phosphoproteins | 1 | 2018 | 2448 | 0.080 |
Why?
|
Phenotype | 3 | 2024 | 16591 | 0.080 |
Why?
|
Adolescent | 11 | 2024 | 88319 | 0.080 |
Why?
|
DNA Repair | 1 | 2017 | 2045 | 0.070 |
Why?
|
Transplantation, Homologous | 2 | 2022 | 4806 | 0.060 |
Why?
|
Lymphocyte Count | 2 | 2021 | 778 | 0.060 |
Why?
|
Albinism | 1 | 2024 | 25 | 0.060 |
Why?
|
Infant, Newborn | 5 | 2023 | 26198 | 0.060 |
Why?
|
Herpesvirus 4, Human | 1 | 2010 | 1078 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2023 | 64680 | 0.060 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2010 | 612 | 0.060 |
Why?
|
Siblings | 2 | 2022 | 825 | 0.060 |
Why?
|
Alleles | 3 | 2020 | 6863 | 0.050 |
Why?
|
Humans | 19 | 2024 | 761504 | 0.050 |
Why?
|
Young Adult | 6 | 2020 | 59243 | 0.050 |
Why?
|
Genes, Regulator | 1 | 2020 | 373 | 0.040 |
Why?
|
Male | 12 | 2024 | 360804 | 0.040 |
Why?
|
Female | 11 | 2024 | 392644 | 0.030 |
Why?
|
Puberty | 1 | 2020 | 501 | 0.030 |
Why?
|
Phagocytes | 1 | 2018 | 295 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2018 | 491 | 0.030 |
Why?
|
Survival Rate | 1 | 2010 | 12725 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 2115 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2018 | 903 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2018 | 802 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2024 | 2735 | 0.030 |
Why?
|
Prognosis | 3 | 2022 | 29625 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6484 | 0.030 |
Why?
|
Gene Silencing | 1 | 2020 | 1509 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3305 | 0.030 |
Why?
|
Adult | 5 | 2020 | 221177 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.030 |
Why?
|
Animals | 1 | 2024 | 168459 | 0.020 |
Why?
|
Myeloablative Agonists | 1 | 2012 | 209 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2023 | 80636 | 0.020 |
Why?
|
Virus Diseases | 1 | 2017 | 718 | 0.020 |
Why?
|
Autoimmunity | 1 | 2019 | 1356 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17904 | 0.020 |
Why?
|
Pedigree | 1 | 2018 | 4542 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 2012 | 712 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 11742 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4278 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5789 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2012 | 606 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54425 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2020 | 3396 | 0.020 |
Why?
|
Neutrophils | 1 | 2020 | 3767 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2012 | 1560 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39106 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 4174 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 12990 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10090 | 0.020 |
Why?
|
Middle Aged | 3 | 2019 | 220895 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10508 | 0.020 |
Why?
|
Time Factors | 1 | 2006 | 39967 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2018 | 12795 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13506 | 0.010 |
Why?
|
United States | 2 | 2022 | 72334 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3819 | 0.010 |
Why?
|
Inflammation | 1 | 2019 | 10773 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2012 | 10194 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36426 | 0.010 |
Why?
|